Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2280350 | 0.99 | SLC6A4 (0.57) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2283918 | 0.87 | SLC6A4 (0.61) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL2280283 | 0.86 | SLC6A4 (0.60) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2284985 | 0.84 | SLC6A4 (0.57) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL2279813 | 0.83 | SLC6A4 (0.56) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2282395 | 0.83 | SLC6A4 (0.58) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL2285095 | 0.82 | SLC6A4 (0.57) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2285035 | 0.81 | SLC6A4 (0.56) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL3380610 | 0.81 | SLC6A4 (0.62) | SLC6A4HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2280406 | 0.78 | SLC6A4 (0.66) | SLC6A4HTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | claimed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010059393-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | claimed |
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059393-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | SLC6A4 19/4885HTR2A 2/4885HTR2C 1/4885 |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | SLC6A4 19/4885HTR2A 2/4885HTR2C 1/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | SLC6A4 19/4885HTR2A 2/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.